NHS patients struggling with obesity to get weight loss jab after US popularity

06 June 2023 , 21:30
697     0
The jabs have been popular in the States where they have been used by famous people including Twitter owner Elon Musk (Image: Getty Images/iStockphoto)
The jabs have been popular in the States where they have been used by famous people including Twitter owner Elon Musk (Image: Getty Images/iStockphoto)

Doctors will prescribe a weight loss jab popular in America to patients struggling with obesity, the government has announced.

Ministers will hold a two-year pilot costing £40million that is hoped will reduce pressure on the health service by helping people to shed pounds.

The medicines watchdog NICE approved the use of semaglutide earlier this year after finding it was safe, effective and affordable.

The drug, which is marketed as Wegovy, is injected into the skin. It makes people feel fuller and more satisfied, so they eat less.

The jabs have been popular in the States where they have been used by famous people including owner Elon Musk.

Teachers, civil servants and train drivers walk out in biggest strike in decade qhiddeiqtuiqreinvTeachers, civil servants and train drivers walk out in biggest strike in decade

Evidence from clinical trials suggests people taking the drug can lose up to 15% of their body weight over a year when used alongside nutrition and lifestyle changes.

NHS patients struggling with obesity to get weight loss jab after US popularityRishi Sunak announced the extended rollout as he flew to the US where he is to hold meetings with Joe Biden (PA)

In March, NICE announced that the injections would be made available to around 35,000 people using specialist weight management services in.

The new pilot will look at how this can be expanded so the jabs can be prescribed to patients by their GPs.

announced the extended rollout as flew to the US last night for a two day visit.

The Prime Minister said: “Obesity puts huge pressure on the NHS.

“Using the latest drugs to support people to lose weight will be a game-changer by helping to tackle dangerous obesity-related health conditions such as high, diabetes and cancer – reducing pressure on hospitals, supporting people to live healthier and longer lives, and helping to deliver on my priority to cut NHS waiting lists.”

Obesity is one of the leading causes of severe health conditions such as cardiovascular disease, diabetes and cancer. It costs the NHS around £6.5billion a year.

According to the government, there were more than one million admissions to hospitals in 2019/2020 when obesity was a factor.

Ministers hope that using the latest treatments to tackle obesity will contribute to cutting waiting lists by reducing the number of people who suffer from weight-related illnesses.

Overweight patients tend to need more support from the NHS and in some cases end up needing operations such as gallstone removal or hip and knee replacements.

Greggs, Costa & Pret coffees have 'huge differences in caffeine', says reportGreggs, Costa & Pret coffees have 'huge differences in caffeine', says report

NHS medical director Professor Sir Stephen Powis said: “Tackling obesity is a key part of the NHS Long Term Plan – it can have devastating consequences for the nation’s health, leading to serious health conditions and some common cancers as well as resulting in significant pressure on NHS services.

“Pharmaceutical treatments offer a new way of helping people with obesity gain a healthier weight and this new pilot will help determine if these medicines can be used safely and effectively in non-hospital settings as well as a range of other interventions we have in place.

“NHS England is already working to implement recommendations from NICE to make this new class of treatment available to patients through established specialist weight management services, subject to negotiating a secure long-term supply of the products at prices that represent value for money taxpayers.”

* Follow Mirror Politics on,, and.

John Stevens

Print page

Comments:

comments powered by Disqus